Jonathan Van Ness is seen on the Netflix show, Queer Eye. He has, for the first time, spoken publicly about using weight loss ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

GLP-1 weight-loss users shift their spending on food purchases both in and out of home. At grocery retail, they are spending more on foods that support GLP-1 balance, including vegetables, eggs and ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH),which is expected to begin in 2H 2025Phase 1 ...